Literature DB >> 8594942

Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men.

P J Hunt1, E A Espiner, A M Richards, T G Yandle, C Frampton, M G Nicholls.   

Abstract

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are both circulating plasma hormones that are secreted by the heart and have similar physiological effects. We have shown previously that abrupt increases in plasma BNP in normal humans impair the clearance of ANP from plasma and result in additive physiological effects. Because large increases in plasma ANP are reported to have no effect on plasma BNP levels in patients with heart failure, we have studied ANP-BNP interactions in eight normal male subjects receiving background infusions of BNP (2 pmol.kg-1.min-1 for 5 h). Each subject also received a coinfusion of ANP ("active" day, 2 pmol.kg-1.min-1 for 2 h) or vehicle ("placebo" day) using a balanced random order, single-blind design. Metabolic clearance rate of ANP (mean 4.1 +/- 0.6 l/min) and disappearance rate from the plasma (t1/2 3.4 +/- 0.3 min) were similar to values measured previously in the absence of exogenous BNP. In contrast, steady-state plasma BNP levels were reversibly increased (mean BNP increment 10 pmol/l) during the administration of ANP (P = 0.038). Associated with these changes were significant (additive) physiological effects. Thus the addition of ANP increased plasma and urine guanosine 3',5'-cyclic monophosphate (P < 0.001 for both) and lowered systolic blood pressure (P = 0.049). When ANP was coinfused, significant differences were also observed in urine volume (P = 0.001) and sodium excretion (P = 0.043) between the infusion period (when urine volume and sodium excretion were enhanced) and postinfusion period (when values decreased). Taken together, our findings of similar interactions between ANP-BNP and BNP-ANP infusions occurring at pathophysiological concentrations of these two peptides, suggest that the interactions result from dissociation of prebound hormone, presumably from biological or clearance receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594942     DOI: 10.1152/ajpregu.1995.269.6.R1397

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

Review 1.  Brain natriuretic peptide and optimal management of heart failure.

Authors:  Nan Li; Jian-An Wang
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

2.  ANP is cleared much faster than BNP in patients with congestive heart failure.

Authors:  Kuniko Kimura; Yukinari Yamaguchi; Manabu Horii; Hiroyuki Kawata; Hiromitsu Yamamoto; Shiro Uemura; Yoshihiko Saito
Journal:  Eur J Clin Pharmacol       Date:  2007-05-04       Impact factor: 2.953

3.  Effect of statin therapy on plasma C-type Natriuretic Peptides and Endothelin-1 in males with and without symptomatic coronary artery disease.

Authors:  Timothy C R Prickett; Richard W Troughton; Eric A Espiner
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

4.  Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.

Authors:  Erica M Dillon; Shouzuo D Wei; Deepak K Gupta; Hui Nian; Brooks S Rodibaugh; Katherine N Bachmann; Allen J Naftilan; Lynne W Stevenson; Nancy J Brown
Journal:  J Card Fail       Date:  2021-06-13       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.